Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared, according to a study in Clinical Cancer Research, a journal ...
Jun 28, 2011
0
0
An interim analysis of a phase II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated both in patients who are undergoing treatment for the first ...
Jun 6, 2011
0
0
A study from Tufts Medical Center researchers published today finds that a novel drug shows promise for treating leukemia patients who have few other options because their disease has developed resistance to standard treatment.
Apr 11, 2011
0
0
A study in Frontiers of Medicine explores the role of the m6A reader YTHDF1 in cardiac fibrosis, a condition characterized by the excessive accumulation of extracellular matrix proteins, leading to the stiffening of the heart ...
Aug 29, 2024
0
0
A new editorial paper titled "The uncharted role of HER2 mutant alleles in breast cancer has been published in Oncotarget.
Nov 6, 2023
0
1
A new editorial paper titled " Impact of cortactin in cancer progression on Wnt5a/ROR1 signaling pathway" has been published in Oncotarget.
Apr 4, 2023
0
24
The journal Oncotarget has published "Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal ...
Nov 2, 2021
0
3
Researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) and The Ohio State University Wexner Medical Center are conducting ...
Jul 29, 2020
0
3
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) today announced results from an extended follow-up analysis of patients in its randomized Phase 3 clinical trial, E1912. The results show that the combination of ibrutinib, ...
Dec 7, 2019
0
4
The German Institute for Quality and Efficiency in Health Care (IQWiG) investigated whether the drug combinations of dabrafenib plus trametinib and of encorafenib plus binimetinib have an added benefit in comparison with ...
Jan 8, 2019
0
4
